Zobrazeno 1 - 10
of 10
pro vyhledávání: '"J Varela González-Aller"'
Autor:
L Enriquez Olivar, E Queipo García, A Muñoz Martin, A Pariente, J Varela González-Aller, F Ramis, S Izquierdo Mñoz
Publikováno v:
Eur J Hosp Pharm
Background Pulmonary hypertension (PH) is a chronic disease with a high mortality rate. Therefore, choosing the right treatment at the right time is essential. Purpose To analyse which treatments were prescribed depending on the type of disease and t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2a58ad18eb482ef32fc78f156910bb7
https://doi.org/10.1136/ejhpharm-2018-eahpconf.509
https://doi.org/10.1136/ejhpharm-2018-eahpconf.509
Publikováno v:
Clinical pharmacy.
Background Refractory coeliac disease (RCD) is a rare but serious complication of coeliac disease and is characterised by non-responsiveness to a gluten free diet in the presence of a clonal population of T lymphocytes within the small intestine. The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e5ccb0341fb8514918aca01437e5558f
https://doi.org/10.1136/ejhpharm-2017-000640.61
https://doi.org/10.1136/ejhpharm-2017-000640.61
Publikováno v:
Patient safety and risk management.
Background Gangrene is defined as ischaemic damage. Fever followed by marked coldness, cyanosis, pain and restricted mobility of extremities should always raise suspicion of gangrene. Intravenous nitroprusside, prostaglandins and hyperbaric oxygen ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dccabf74c2c6e3cf7257259c4bf60852
https://doi.org/10.1136/ejhpharm-2017-000640.563
https://doi.org/10.1136/ejhpharm-2017-000640.563
PS-021 Natalizumab discontinuation in patients diagnosed with relapsing remitting multiple sclerosis
Autor:
MT Sánchez Sánchez, A.M. López González, MN Téllez Lara, MJ Neri Crespo, J Varela González-Aller, ME Cárdaba García
Publikováno v:
Patient safety and risk management.
Background Natalizumab is effective in relapsing remitting multiple sclerosis (RRMS) treatment, although it is associated with serious adverse events that may require therapy discontinuation. Purpose To assess the reasons for discontinuing natalizuma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eea254a4d6d6690ca98ae337780957e2
https://doi.org/10.1136/ejhpharm-2017-000640.527
https://doi.org/10.1136/ejhpharm-2017-000640.527
Autor:
A De Frutos Soto, ME Cárdaba García, J Varela González-Aller, María-Teresa Sánchez, M Izquierdo Navaro
Publikováno v:
Clinical pharmacy.
Background Intravenous immunoglobulins (IVIg) are widely used to treat immunodeficiencies and autoimmune and/or inflammatory diseases, representing a significant economic burden for hospitals. Purpose Disclosing the use of IVIg in a tertiary hospital
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b101397ecfd64f1d511e29cb42b71521
https://doi.org/10.1136/ejhpharm-2017-000640.37
https://doi.org/10.1136/ejhpharm-2017-000640.37
Autor:
M Hernando Verdugo, J Varela González-Aller, T Sánchez Sánchez, ME Cárdaba García, S Fernández Peña, S. Camacho Parreño
Publikováno v:
European Journal of Hospital Pharmacy. 23:A15.2-A16
Background Antiangioagenic drugs, ranibizumab, bevacizumab and the most recent one marketed, aflibercept, are the elected treatments of age related macular degeneration (AMD). These treatments are a heavy economic burden because of the growing number
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5276863afe613b1f9b52109442283338
https://doi.org/10.1136/ejhpharm-2016-000875.35
https://doi.org/10.1136/ejhpharm-2016-000875.35
Autor:
A.M. López González, V Cabezas Martín, ME Cárdaba García, J Varela González-Aller, T Sánchez Sánchez, S Fernández Peña
Publikováno v:
European Journal of Hospital Pharmacy. 23:A63.3-A64
Background Levosimendan is a positive inotropic drug that was approved in our country for the short term treatment of acute decompensation in chronic heart failure in situations where conventional treatment is not sufficient. There are few studies on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::30a97e89ea1d407a8a68dbc8ba6e66f7
https://doi.org/10.1136/ejhpharm-2016-000875.144
https://doi.org/10.1136/ejhpharm-2016-000875.144
Autor:
E Cardaba Perez, J Varela González-Aller, S Fernández Cañabate, V Cabezas Martín, C Cardaba Perez, L García López, S Fernández Peña
Publikováno v:
European Journal of Hospital Pharmacy. 22:A93.1-A93
Background Linezolid is the first oxazolidinone available for clinical use. Linezolid is indicated in the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA) or Streptococcus pneumoniae; and complicated skin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aa72ece9b4a85b39b402f647235b78a2
https://doi.org/10.1136/ejhpharm-2015-000639.223
https://doi.org/10.1136/ejhpharm-2015-000639.223
Autor:
S Fernández Cañabate, C Cardaba Perez, L García López, J Varela González-Aller, E Cárdaba García, S Fernández Peña, V Cabezas Martín
Publikováno v:
European Journal of Hospital Pharmacy. 22:A12.2-A12
Background Behcet’s disease (BD) is an inflammatory disease characterised by recurrent oral aphthous ulcers and numerous potential systemic manifestations. Purpose To describe the experience of our centre with the use of adalimumab, etanercept and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7910f45f859da08886029f088747242a
https://doi.org/10.1136/ejhpharm-2015-000639.28
https://doi.org/10.1136/ejhpharm-2015-000639.28
Autor:
J Varela González-Aller, E Cárdaba García, S Fernández Cañabate, V Cabezas Martín, S Fernández Peña, L García López, C Cardaba Perez
Publikováno v:
European Journal of Hospital Pharmacy. 22:A12.4-A13
Background Diabetic macular oedema (DME) is the main cause of impairment of visual acuity in diabetic patients. The current standard treatment for patients with DME (focal/grid laser photocoagulation) does not usually improve impaired vision, and man
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ef6dd8ee2577c525806e91a9e6c52883
https://doi.org/10.1136/ejhpharm-2015-000639.29
https://doi.org/10.1136/ejhpharm-2015-000639.29